Table 3 Follow-up duration, number of incident cases, crude incidence of hospitalization for infection syndrome and infection-related mortality, and association between different eGFR categories and risk of hospitalization for infection syndrome and infection-related mortality as compared with eGFR 90–105 and younger patients (N = 119,871).

Any infection

CKD stage

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

1,800

282

200,478

19,471

8.98 (8.57–9.40)

14.48 (12.89–16.28)

Stage 1

1,078

2,564

128,575

184,461

8.38 (7.90–8.90)

13.90 (13.37–14.45)

Stage 2

780

5,638

96,666

247,427

8.07 (7.52–8.66)

22.79 (22.20–23.39)

Stage 3

35

2,030

1,266

35,830

27.66 (19.86–38.52)

56.66 (54.24–59.18)

Septicemia

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

159

53

200,478

19,471

0.79 (0.68–0.93)

2.72 (2.08–3.56)

Stage 1

133

476

128,575

184,461

1.03 (0.87–1.23)

2.58 (2.36–2.82)

Stage 2

101

1,139

96,666

247,427

1.04 (0.86–1.27)

4.60 (4.34–4.88)

Stage 3

7

448

1,266

35,830

5.53 (2.64–11.60)

12.50 (11.40–13.72)

Lower respiratory tract infection⁺

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

241

66

200,478

19,471

1.20 (1.06–1.36)

3.39 (2.66–4.31)

Stage 1

171

655

128,575

184,461

1.33 (1.14–1.55)

3.55 (3.29–3.83)

Stage 2

117

1,944

96,666

247,427

1.21 (1.01–1.45)

7.86 (7.52–8.21)

Stage 3

8

791

1,266

35,830

6.32 (3.16–12.64)

22.08 (20.5–23.67)

Intra-abdominal infection

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

316

43

200,478

19,471

1.58 (1.41–1.76)

2.21 (1.64–2.98)

Stage 1

229

341

128,575

184,461

1.78 (1.56–2.03)

1.85 (1.66–2.06)

Stage 2

156

619

96,666

247,427

1.61 (1.38–1.89)

2.50 (2.31–2.71)

Stage 3

3

154

1,266

35,830

2.37 (0.76–7.35)

4.30 (3.67–5.03)

Reproductive and urinary tract infection

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

990

133

200,478

19,471

4.94 (4.64–5.26)

6.83 (5.76–8.10)

Stage 1

487

1,020

128,575

184,461

3.79 (3.47–4.14)

5.53 (5.20~–5.88)

Stage 2

346

2,068

96,666

247,427

3.58 (3.22–3.98)

8.36 (8.01–8.73)

Stage 3

20

773

1,266

35,830

15.80 (10.20–24.50)

21.57 (20.11–23.15)

Skin and soft tissue infection

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

210

31

200,478

19,471

1.05 (0.91–1.20)

1.59 (1.12–2.26)

Stage 1

129

391

128,575

184,461

1.00 (0.84–1.19)

2.12 (1.92–2.34)

Stage 2

121

737

96,666

247,427

1.25 (1.05–1.50)

2.98 (2.77–3.20)

Stage 3

3

256

1,266

35,830

2.37 (0.76–7.35)

7.14 (6.32–8.08)

Mortality from any infection

<50

≥50

<50

≥50

<50

≥50

Stage 1 high

10*

4

20,7592

20,571

0.02 (0.01–0.04)*

0.19 (0.07–0.52)

Stage 1

33

132,727

193,773

0.17 (0.12–0.24)

Stage 2

222

99,643

265,487

0.84 (0.73–0.95)

Stage 3

123

1,395

41,784

2.94 (2.47–3.51)